GSK plc reported a strong Q1 2026 performance with total sales of £7.6 billion and core operating profit growth of 10%, primarily driven by Specialty Medicines totaling £3.2 billion, which increased by 14%. The company declared a dividend of 17p per share and maintains its guidance for 2026 sales growth of 3-5% and core operating profit growth of 7-9%.